NMDA glutamate receptor subunit 2B (GluN2B)

The NMDA glutamate receptor subunit 2B (GluN2B) is an essential component of the N-methyl-D-aspartate (NMDA) receptor, a ligand-gated ion channel found predominantly in the central nervous system[1][4][5]. NMDA receptors are typically heterotetramers composed of two GluN1 and two GluN2 subunits; the GluN2B subunit imparts specific biophysical and pharmacological properties, including high calcium permeability, slower gating kinetics, sensitivity to magnesium block, and responsiveness to certain subtype-specific antagonists[1][2][4][5]. GluN2B-containing NMDA receptors are highly expressed in the developing and adult forebrain, contribute significantly to synaptic plasticity, learning, and memory, and play a crucial role in the regulation of dendritic spine morphology and postsynaptic complex assembly[3][5]. They are implicated in diverse neurological and psychiatric disorders, making them important targets for therapeutic drug development. Selective GluN2B antagonists are being explored as treatments for depression, pain, and neurodegenerative diseases, though clinical development is challenged by safety concerns related to cognition and synaptic function[7][5][3].

Other names

NR2BGluRε2GRIN2BN-methyl-D-aspartate receptor subunit 2B

Allosteric antagonism (inhibitors bind specifically to GluN2B and inhibit receptor function); Noncompetitive antagonism; Channel blockade (some drugs block the ion channel pore)